

Information for Pharmacists

**Claims Submission Procedure –
COVID-19 Oral Antiviral Drugs
*Effective May 20, 2022
Updated May 28, 2024***

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

- This Claims Submission Procedure (CSP) applies to community pharmacy dispensation of commercially procured COVID-19 oral antiviral drugs to any person in Manitoba with a valid prescription. This is not limited to residents of Manitoba. A Manitoba Health Registration card is not required for coverage.
- COVID-19 oral antiviral drug(s) include:
 - Paxlovid (nirmatrelvir and ritonavir) – Drug Identification Number 02524031
 - Paxlovid (nirmatrelvir and ritonavir) for moderate renal impairment – Drug Identification Number 02527804
- Paxlovid is now available to order commercially in Manitoba. Pharmacies should procure commercially available Paxlovid through usual distribution channels for provision to clients at no cost now that there is no more federally procured Paxlovid available.
- When dispensing commercially procured Paxlovid:
 - Clients presenting with a prescription must not be charged any out-of-pocket costs and even if the client is enrolled in Pharmacare or another provincial drug program (e.g., Family Services/EIA) or federal drug program; there is no requirement to meet a deductible or co-pay.
 - A professional fee of \$14 will be reimbursed to pharmacies per treatment course dispensed. The professional fee includes any associated delivery fees. For added clarity, pharmacies may not charge any additional fees for this product or associated services.
 - The department will reimburse an ingredient cost equal to the actual acquisition cost of the product.
- Failure to submit the claim according to one of the procedures above will result in no reimbursement to the pharmacy for the allowable professional fee or ingredient cost.

Submission Procedure for Manitobans WITH a Personal Health Identification Number (PHIN):

- Submit claim via drug utilization (DU) only.
- DO NOT submit claim to DPIN for **fiscal** adjudication.
- Submit a completed [DPIN Reversal/Adjustment Form](#). Write “ATTENTION PAXLOVID” at the top of the form.
- Indicate the quantity of each Paxlovid pre-packaged treatment course dispensed as:
 - 30 for full treatment course dispensed (for DIN 02524031, or the adjustment of two packages of DIN 02527804 for clients requiring full dose Paxlovid)
 - 20 for moderate renal impairment dosing treatment course dispensed (for DIN 02527804, or if this product is unavailable for DIN 02524031)
- Indicate the total days’ supply of Paxlovid as five (5).
- Enter an ingredient cost equal to the actual acquisition cost of the product.
- Enter a maximum Professional Fee of \$14.

Submission Procedure for Manitobans WITHOUT a Personal Health Identification Number:

- Complete a [COVID-19 ORAL Antiviral Drug Claim Form – Client without a Manitoba Health PHIN](#) and submit to DPIN via fax within 28 days of dispensation.
- Enter a maximum Professional Fee of \$14.

If the client has a PHIN, the claim MUST be entered into DPIN.

- **Pharmacy will NOT see the professional fee or ingredient cost paid to them at time of on-line claim submission.**
- **Reimbursement for COVID-19 oral antiviral drug claims will be reimbursed via electronic funds transfer once the claim has been processed. Reimbursement will appear on corresponding pharmacy statement. One adjustment per claim.**
- If a claim is submitted and not dispensed to patient, the pharmacy must reverse the claim on-line within 28 days of claim date.
- If a claim is submitted, and not dispensed to patient, and not reversed within 28 days, the pharmacy must submit a reversal/adjustment form.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at: <https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to PDPIInfoAudit@gov.mb.ca.